Description de l'entreprise
The Group managed by 4SC AG (ISIN DE000A14KL72) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies.
Conseil d'administration & Conseil de surveillance
| PDG |
| Dr. Jason Loveridge |
| Conseil d'administration |
| Dr. med. Frank Hermann, Dr. med. Susanne Danhauser-Riedl |
| Conseil de surveillance |
| Dr. Clemens Doppler, Joerg von Petrikowsky, Dr. Irina Antonijevic, Dr. Manfred Rüdiger, Helmut Jeggle, Prof. Dr. Helga Rübsamen-Schaeff |
Données de l'entreprise
| Nom: |
4SC AG |
| Adresse: |
Fraunhoferstraße 22,D-82152 Planegg-Martinsried |
| Téléphone: |
+49-89-700763-0 |
| Fax: |
+49-89-700763-29 |
| Courriel: |
-
|
| Internet: |
www.4sc.de |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
26.00% |
| IPO date: |
15/12/2005 |
Relations avec les investisseurs
| Nom: |
- |
| Téléphone IR: |
- |
| IR-Fax: |
- |
| E-mail IR: |
ir-pr@4sc.com
|
